ArticleFrontiers in endocrinology2026
The dual role of urinary C-peptide/creatinine ratio: predicting insulin resistance in non-diabetic adults and microvascular complications risk in patients with type 2 diabetes.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Insulin resistance (IR) is a key driver of type 2 diabetes mellitus (T2DM) onset, and diabetic microvascular complications (DMC) represent its poor prognosis. However, simple and non-invasive screening methods for detection of IR and DMC are limited. The urinary C-peptide/creatinine ratio (UCPCR) can be used to measure β-cell function, and we aimed to evaluate its utility as a surrogate marker for IR in non-diabetic individuals and for DMC risk in patients with T2DM. Methods: This cross-sectional study enrolled 447 individuals (255 non-diabetic adults and 192 T2DM patients) from November 2023 to September 2025. The non-diabetic cohort was divided into IR and non-IR groups according to the Matsuda index. The diabetic cohort was divided into DMC and non-DMC groups. Fasting UCPCR (0hUCPCR) and 2-h post-OGTT/steamed bread meal (2hUCPCR) were measured. Multiple regression analysis was used to describe the association between UCPCR and the Matsuda index or DMC. Diagnostic accuracy was assessed using receiver operating characteristic (ROC) curve analysis. Results: In the non-diabetic individuals, both 0hUCPCR and 2hUCPCR were higher in the IR group, and they were negatively associated with the Matsuda index ( Conclusion: Both 0hUCPCR and 2hUCPCR are promising markers for IR in non-diabetic adults, and 2hUCPCR is associated with lower risk of DMC in T2DM patients. Coupled with their practical advantages of simplicity and non-invasiveness, UCPCRs are promising tools for future large-scale screening in at-risk populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.